ABSTRACT
Yet, there are solutions in place that appear to be directed at the soft spots in the current R&D framework, especially open science initiatives exemplified by the Oncology Biomarker Qualification Initiative with $6.27 million from approximately ten companies and $3.75 million from the NIH’s National Cancer Institute in the United States. Another example is an education and training program, supported by the Wellcome Trust and seven big pharma firms, to address the MD-researcher shortage at UK universities.In addition to TM providing academia with funding opportuni�ties from external sources through partnerships with the private sector, there is a promising trend in terms of its capacity to attract grant funding, mostly from the public sector (Fig. 40.1).
